HomeCompareESALF vs NNN

ESALF vs NNN: Dividend Comparison 2026

ESALF yields 3.60% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NNN wins by $185.00 in total portfolio value· pulled ahead in Year 10
10 years
ESALF
ESALF
● Live price
3.60%
Share price
$30.00
Annual div
$1.08
5Y div CAGR
0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$474.23
Full ESALF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — ESALF vs NNN

📍 NNN pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALF
Annual income on $10K today (after 15% tax)
$306.00/yr
After 10yr DRIP, annual income (after tax)
$403.10/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $1,838.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALF + NNN for your $10,000?

ESALF: 50%NNN: 50%
100% NNN50/50100% ESALF
Portfolio after 10yr
$25.5K
Annual income
$1,555.82/yr
Blended yield
6.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ESALF
No analyst data
Altman Z
2.9
Piotroski
7/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALF buys
0
NNN buys
0
No recent congressional trades found for ESALF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALFNNN
Forward yield3.60%5.68%
Annual dividend / share$1.08$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.4%8.6%
Portfolio after 10y$25.4K$25.6K
Annual income after 10y$474.23$2,637.42
Total dividends collected$4.2K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ESALF vs NNN ($10,000, DRIP)

YearESALF PortfolioESALF Income/yrNNN PortfolioNNN Income/yrGap
1$11,061$361.44$10,737$617.02+$324.00ESALF
2$12,211$375.14$11,577$710.93+$634.00ESALF
3$13,454$388.58$12,538$822.59+$916.00ESALF
4$14,798$401.74$13,645$956.06+$1.2KESALF
5$16,248$414.60$14,925$1,116.51+$1.3KESALF
6$17,813$427.16$16,415$1,310.57+$1.4KESALF
7$19,499$439.41$18,158$1,546.77+$1.3KESALF
8$21,315$451.34$20,213$1,836.20+$1.1KESALF
9$23,270$462.94$22,649$2,193.37+$621.00ESALF
10← crossover$25,373$474.23$25,558$2,637.42$185.00NNN

ESALF vs NNN: Complete Analysis 2026

ESALFStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ESALF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALF vs SCHDESALF vs JEPIESALF vs OESALF vs KOESALF vs MAINESALF vs ADCESALF vs EPRTESALF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.